Previous 10 | Next 10 |
home / stock / eprx:cc / eprx:cc news
Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial Results PR Newswire VICTORIA, BC , April 1, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company leveraging its propr...
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VICTORIA, British Columbia, March 15, 2024 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company, today announced that it has closed i...
Canadian Investment Regulatory Organization Trade Resumption - EPRX Canada NewsWire TORONTO , March 12, 2024 /CNW/ - Trading resumes in: Company: Eupraxia Pharmaceuticals Inc. TSX Symbol: EPRX All Issues: Yes Resumption (ET): 10:00 AM CIRO can...
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VICTORIA, British Columbia, March 12, 2024 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company, today announced that it has priced i...
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VICTORIA, British Columbia, March 11, 2024 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company, today announced the launch of an ove...
Canadian Investment Regulatory Organization Trading Halt - EPRX Canada NewsWire TORONTO , March 11, 2024 /CNW/ - The following issues have been halted by CIRO: Company: Eupraxia Pharmaceuticals Inc. TSX Symbol: EPRX All Issues: Yes Reason: Pending New...
Eupraxia Pharmaceuticals Announces Updated Positive Clinical Data in EP-104GI RESOLVE Trial for the Treatment of Eosinophilic Esophagitis Canada NewsWire No serious or treatment related adverse events in either the first or second cohort Second cohort demonstrated an avera...
Eupraxia Pharmaceuticals Initiates Phase 3 Development Program for EP-104IAR Canada NewsWire Decision to proceed with Phase 3 follows completion of End-of-Phase 2 meeting with the U.S. FDA VICTORIA, BC , Feb. 1, 2024 /CNW/ - Eupraxia Pharmaceuticals ...
Eupraxia Pharmaceuticals Announces Positive Data from MRI Exploratory Sub-Study in Phase 2 SPRINGBOARD Trial Evaluating the Safety and Efficacy of EP-104IAR for the Treatment of Osteoarthritis of the Knee Canada NewsWire EP-104IAR demonstrates trends to reduction in joint infl...
Eupraxia Pharmaceuticals Announces Filing of Preliminary MJDS Base Shelf Prospectus Canada NewsWire VICTORIA, BC , Jan. 8, 2024 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) today announced that it has filed and obtained a r...
News, Short Squeeze, Breakout and More Instantly...
Eupraxia Pharmaceuticals Inc. Company Name:
EPRX:CC Stock Symbol:
TSXC Market:
Eupraxia Pharmaceuticals Inc. Website:
Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo Canada NewsWire VICTORIA, BC , July 8, 2024 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnolo...
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024 Canada NewsWire Osteoarthritis ("OA") is the leading cause of disability in older adults. The U.S. Centers for Disease Control an...
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders Canada NewsWire VICTORIA, BC , June 6, 2024 /CNW/ - Eupraxia Pharmaceuticals Inc. (" Eupraxia " or the " Company ") (TSX: EPRX) (NASDAQ: EPRX), a cli...